
Senores Pharmaceuticals IPO
- Issue price
- ₹391
- Listing price
- ₹600
- +53.45%
- Current price
- ₹1,174.6
- +200.41%
- Subscribed
- 96.96x
- Issue size
- ₹582.11 Cr
- Listed on
- 30 Dec 2024
IPO timeline
- Opens20 DecFri
- Closes24 DecTue
- Allotment26 DecThu
- Refunds27 DecFri
- Demat credit27 DecFri
- Listing30 DecMon
Issue details
- Price band
- ₹372 – ₹391 per share
- Issue size
- ₹582.11 Cr
- Fresh issue
- Not available
- Offer for sale
- Not available
- Issue type
- Fresh capital cum OFS
- Face value
- ₹10 per share
- Lot size
- 38 shares
- Minimum investment
- ₹14,858
- Listing on
- BSE, NSE
- Exchange code
- SENORES · 544319
This issue combines a fresh issue and an offer for sale. The amounts for each part are not available in our data; see the offer document for the split.
Lot size and investment
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 38 | ₹14,858 |
| Retail (Max) | 13 | 494 | ₹1,93,154 |
| S-HNI (Min) | 14 | 532 | ₹2,08,012 |
| B-HNI (Min) | 68 | 2,584 | ₹10,10,344 |
Reservation
- QIB
- 1,11,09,543 shares (75.00% of the Offer)
- NII
- 22,21,908 shares (15.00% of the Offer)
- Retail
- 14,81,272 shares (10.00% of the Offer)
- Employee
- 75,000 shares (0.50% of the Offer)
Allotment status
The allotment for this IPO is final. Check whether you received shares on the registrar's website using your PAN, application number or demat account (DP / Client ID).
Check allotment on MUFG Intime India- 1Open the registrar's allotment page and select this IPO from the list.
- 2Enter your PAN, application number or DP / Client ID.
- 3Submit to see the number of shares allotted, if any.
- Basis of allotment
- 26 Dec 2024
- Refunds initiated
- 27 Dec 2024
- Shares credited to demat
- 27 Dec 2024
- Listing
- 30 Dec 2024
Grey market premium (GMP)
- Current GMP
- ₹270
- +69.00%
- Estimated listing price
- ₹661
- Issue price ₹391
- Highest
- ₹270
- 27 Dec
- Lowest
- ₹120
- 18 Dec
GMP by day (₹ per share)
Day-wise GMP table
| Date | GMP | Premium | Est. listing |
|---|---|---|---|
| 27 Dec 2024 | ₹270 | +69.00% | ₹661 |
| 26 Dec 2024 | ₹230 | +59.00% | ₹621 |
| 24 Dec 2024 | ₹230 | +59.00% | ₹621 |
| 23 Dec 2024 | ₹220 | +56.00% | ₹611 |
| 22 Dec 2024 | ₹190 | +49.00% | ₹581 |
| 19 Dec 2024 | ₹140 | +36.00% | ₹531 |
| 18 Dec 2024 | ₹120 | +31.00% | ₹511 |
- Kostak rate
- ₹0
GMP is an unofficial indicator from an unregulated market. It is shown for information only and is not a prediction of the listing price or a recommendation to apply.
Subscription status
- QIB97.84x
- NII (HNI)100.35x
- Retail93.16x
Financials
- P/E Ratio
- 28.21
- EPS (₹)
- 13.86
- RoE
- 23.60%
- RoCE
- 11.73%
- RoNW
- 23.60%
- PAT Margin
- 15.25%
- Debt / Equity
- 1.07
- NAV (₹)
- 66.96
Separate pre- and post-issue P/E are not available for this IPO; the P/E shown is as disclosed for the issue.
| Period ended | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets | 678.08 | 621.88 | 131.05 | 59.15 |
| Total Income | 183.35 | 217.34 | 39.02 | 14.63 |
| Profit After Tax | 23.94 | 32.71 | 8.43 | 0.99 |
| NET Worth | 319.06 | 231.71 | 45.50 | 36.59 |
| Total Borrowing | 242.03 | 248.38 | 60.76 | 14.21 |
Peer comparison
| Company | Issue size | P/E | RoNW | PAT margin | Subscribed | Listing gain |
|---|---|---|---|---|---|---|
| Senores Pharmaceuticals This IPO | ₹582.11 Cr | 28.21 | 23.60% | 15.25% | 96.96x | +53.45% |
| Innova Captab Mainboard · listed 29 Dec 2023 | ₹570 Cr | 36.42 | 24.58% | 7.34% | 56.33x | +0.92% |
| GPT Healthcare Mainboard · listed 29 Feb 2024 | ₹525.14 Cr | 32.49 | 23.77% | 10.64% | 8.52x | +15.59% |
| Corona Remedies Mainboard · listed 15 Dec 2025 | ₹655.37 Cr | 58.26 | 24.65% | 12.49-13.33% | 137.04x | +38.42% |
| Gandhar Oil Refinery (India) Mainboard · listed 30 Nov 2023 | ₹500.69 Cr | 7.62 | 32.28% | 5.20% | 65.63x | +76.33% |
| Fusion CX Mainboard · listed 22 Oct 2026 | ₹702 Cr | 18.73 | 9.12% | 11.36% | 4.45x | +5.54% |
| Sahajanand Medical Technologies Mainboard · listed 23 Oct 2026 | ₹475.48 Cr | 57.91 | 2.31% | 4.29% | 14.2x | +7.89% |
Peers are other recent IPOs from the same industry, closest in issue size. Ratios are as disclosed at the time of each issue. This is not the listed-peer table from the offer document.
IPO objectives
How Senores Pharmaceuticals plans to use the money raised, as stated in the offer document.
- Investment in one of the Subsidiaries, Havix, to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in our Atlanta Facility₹107 Cr
- Re-payment/pre-payment, in full or in part, of certain borrowings availed by the Company₹73.48 Cr
- Investment in our Subsidiary, namely, Havix, for re- payment/pre-payment in full or in part, of certain borrowings availed by such Subsidiaries₹20.22 Cr
- Funding the working capital requirements of the Company₹43.26 Cr
- Investment in the Subsidiaries, namely, SPI and Ratnatris to fund their working capital requirements₹59.48 Cr
- Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes₹154.37 Cr
About Senores Pharmaceuticals
Senores Pharmaceuticals Limited was incorporated as Senores Pharmaceuticals Private Limited on 26 December 2017. It is a global research driven pharmaceutical company developing and making generic products in the B2B segment. It mainly serves regulated markets such as the US, Canada and the United Kingdom across therapy areas and dosage forms, and focuses on speciality and complex niche products. Its promoters are Swapnil Jatinbhai Shah and Ashokkumar Vijaysinh Barot. The IPO was Rs 582.11 crore, with Rs 500.00 crore of fresh issue and Rs 82.11 crore of offer for sale by promoters, a promoter group member and another shareholder. Fresh money was planned for a sterile injectable plant, repaying borrowings and working capital.
Strengths
- Total income rose from Rs 14.63 crore in FY2022 to Rs 217.34 crore in FY2024.
- Profit after tax rose from Rs 0.99 crore in FY2022 to Rs 32.71 crore in FY2024.
- Profit after tax was Rs 23.94 crore in the six months to 30 September 2024.
- Rs 500.00 crore of the issue was fresh capital for a new plant and debt repayment.
- The source puts the PAT margin at 15.25%.
Risks
- The pre-issue P/E was 39.77 at the upper band of Rs 391, based on EPS of Rs 9.83.
- Total borrowing rose from Rs 14.21 crore on 31 March 2022 to Rs 242.03 crore on 30 September 2024.
- Growth has come very fast, from total income of Rs 39.02 crore in FY2023, including through acquisitions, which needs strong integration.
- US and other regulated markets have strict inspections and pricing pressure, and the source puts debt to equity at 1.07.
- Promoters and the promoter group held 66.67% before the issue and 45.77% after it.
Promoters and shareholding
Swapnil Jatinbhai Shah and Ashokkumar Vijaysinh Barot
- Promoter holding, pre-issue
- 66.67%
- Promoter holding, post-issue
- 45.77%
Registrar, lead managers and documents
Documents
Senores Pharmaceuticals IPO: common questions
1.When does the Senores Pharmaceuticals IPO open and close?
The Senores Pharmaceuticals IPO opens on 20 Dec 2024 and closes on 24 Dec 2024.
2.What is the price band of the Senores Pharmaceuticals IPO?
The price band is ₹372 – ₹391 per share, with a lot size of 38 shares and a minimum investment of ₹14,858.
3.What is the size of the Senores Pharmaceuticals IPO?
The issue size is ₹582.11 Cr (Fresh capital cum OFS).
4.What is the GMP of the Senores Pharmaceuticals IPO?
The last reported grey market premium is ₹270 per share as of 27 Dec 2024, 12:00 PM IST. GMP is unofficial and changes frequently.
5.When is the Senores Pharmaceuticals IPO allotment?
The basis of allotment is expected on 26 Dec 2024. Allotment status can be checked with the registrar, MUFG Intime India Private Limited.
6.When will the Senores Pharmaceuticals IPO list?
The shares listed on 30 Dec 2024 on BSE, NSE.
7.Who is the lead manager of the Senores Pharmaceuticals IPO?
The book running lead managers are Nuvama Wealth Management Ltd., Ambit Capital, Equirus Capital Pvt.Ltd., and the registrar is MUFG Intime India Private Limited.
8.What will the money raised in the Senores Pharmaceuticals IPO be used for?
As stated in the offer document, the proceeds are for: Investment in one of the Subsidiaries, Havix, to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in our Atlanta Facility; Re-payment/pre-payment, in full or in part, of certain borrowings availed by the Company; Investment in our Subsidiary, namely, Havix, for re- payment/pre-payment in full or in part, of certain borrowings availed by such Subsidiaries; Funding the working capital requirements of the Company; Investment in the Subsidiaries, namely, SPI and Ratnatris to fund their working capital requirements.
9.How can my company launch an IPO like Senores Pharmaceuticals?
Start with an IPO readiness assessment: eligibility for the Main Board, audited financials, governance, conversion to a public limited company and an indicative valuation. Be IPO Ready advises promoters through each step, from readiness to listing day.
For business owners
Your company could be the next listing
Businesses like these raise growth capital on the public markets every week. Tell us about yours and our advisors will tell you, plainly, whether an IPO is within reach and what it would take.
- Eligibility check against NSE Emerge, BSE SME and Main Board norms
- Indicative valuation and issue size for your business
- A clear timeline from readiness to listing day
Check if your business can list
Fill in the eligibility form and get an assessment of where you stand. It takes about five minutes.
Prefer to talk? Call +91 92130 20393